BiotechTube

Pegtibatinase

Phase 3Recruiting
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Homocystinuria

Conditions

Homocystinuria

Trial Timeline

Apr 30, 2024 → Jan 1, 2027

NCT ID
NCT06431893

About Pegtibatinase

Pegtibatinase is a phase 3 stage product being developed by Travere Therapeutics for Homocystinuria. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06431893. Target conditions include Homocystinuria.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT06431893Phase 3Recruiting
NCT06247085Phase 3Active

Competing Products

3 competing products in Homocystinuria

See all competitors
ProductCompanyStageHype Score
SYNB1353SynlogicPhase 1
25
PegtibatinaseTravere TherapeuticsPhase 3
72
Pegtibatinase + PlaceboTravere TherapeuticsPhase 1/2
36

Other Products from Travere Therapeutics

SparsentanApproved
80
PegtibatinasePhase 3
72
sparsentan + IrbesartanPhase 3
72
Fosmetpantotenate + PlaceboPhase 3
72
sparsentan + irbesartan + DapagliflozinPhase 3
72